Next Steps Following Phase 2 Trial Assessing Niraparib in Treatment of Uterine Serous Carcinoma

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

During this interview, Frimer discussed next steps following the results of the phase 2 trial assessing niraparib.

Marina Frimer: If positive results are noted, then the next steps would hopefully include a phase 3 design. However, given the rarity of this disease, a phase 3 trial may be very difficult to accomplish, and, therefore, we hope that the phase 2 design will be telling in our future treatment of women with uterine serious cancer and will hopefully change the algorithm of treatment in general.